SEARCH

SEARCH BY CITATION

References

  • 1
    Adriaansen, H.J., Van, D.J., Kappers, K.M., Hahlen, K., Van't Veer, M.B., De Wijdenes, B.J., Holdrinet, A.C., Harthoorn, L.E., Abels, J., Hooijkaas, H. (1990) Terminal deoxynucleotidyl transferase positive subpopulations occur in the majority of ANLL: implications for the detection of minimal disease. Leukemia, 4, 404 410.
  • 2
    Adriaansen, H.J., Jacobs, B.C., Kappers, K.M., Hahlen, K., Hooijkaas, H., Van D.J. (1993) Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia, 7, 472 481.
  • 3
    Ashman, L.K., Cambareri, A.C., To, L.B., Levinsky, R.J., Juttner, C.A. (1991) Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood, 78, 30 37.
  • 4
    Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Annals of Internal Medicine, 103, 620 625.
  • 5
    Campana, D. & Pui, C.H. (1995) Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood, 85, 1416 1434.
  • 6
    Campana, D., Coustan, S.E., Janossy, G. (1990) The immunologic detection of minimal residual disease in acute leukemia. Blood, 76, 163 171.
  • 7
    Del Canizo, M.C., San Miguel, J.F., Gonzalez, M., Anta, J.P., Orfao, A., Lopez, B.A. (1987) Discrepancies between morphologic, cytochemical, and immunologic characteristics in acute myeloblastic leukemia. American Journal of Clinical Pathology, 88, 38 42.
  • 8
    Chang, K.S., Lu, J.F., Wang, G., Trujillo, J.M., Estey, E., Cork, A., Chu, D.T., Freireich, E.J., Stass, S.A. (1992) The t (15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction. Blood, 79, 554 558.
  • 9
    Cheson, B.D., Cassileth, P.A., Head, D.R., Schiffer, C.A., Bennett, J.M., Bloomfield, C.D., Brunning, R., Gale, R.P., Grever, M.R., Keating, M.J., Sawitsky, A., Stass, S., Weinstein, H., Woods, W.G. (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology, 8, 813 819.
  • 10
    Foroni, L., Harrison, C.J., Hoffbrand, A.V., Potter, M.N. (1999) Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukemia by molecular analysis. British Journal of Haematology, 105, 7 24.
  • 11
    Greaves, M., Paxton, A., Janossy, G., Pain, C., Johnson, S., Lister, T.A. (1980) Acute lymphoblastic leukaemia associated antigen. III. Alterations in expression during treatment and in relapse. Leukemia Research, 4, 1 14.
  • 12
    Huang, W., Sun, G.L., Li, X.S., Cao, Q., Lu, Y., Jang, G.S., Zhang, F.Q., Chai, J.R., Wang, Z.Y., Waxman, S., Chen, Z., Chen, S.J. (1993) Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood, 82, 1264 1269.
  • 13
    Keating, M.J., Smith, T.L., Kantarjian, H., Cork, A., Walters, R., Trujillo, J.M., McCredie, K.B., Gehan, E.A., Freireich, E.J. (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia, 2, 403 412.
  • 14
    Macedo, A., Orfao, A., Vidriales, M.B., Lopez, B.M., Valverde, B., González, M., Caballero, M.D., Ramos, F., Martinez, M., Fernandez, C.J., Martínez, A., San Miguel, J.F. (1995a) Characterization of aberrant phenotypes in acute myeloblastic leukemia. Annals of Hematology, 70, 189 194.DOI: 10.1007/s002770050054
  • 15
    Macedo, A., Orfao, A., Martinez, A., Vidriales, M.B., Valverde, B., Lopez, B.M., San Miguel, J.F. (1995b) Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML. British Journal of Haematology, 89, 338 341.
  • 16
    Macedo, A., Orfao, A., Ciudad, J., Gonzalez, M., Vidriales, B., Lopez, B.M., Martinez, A., Landolfi, C., Canizo, C., San, M.J. (1995c) Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia, 9, 1896 1901.
  • 17
    Miller, W.J., Levine, K., DeBlasio, A., Frankel, S.R., Dmitrovsky, E., Warrell, R.J. (1993) Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood, 82, 1689 1694.
  • 18
    Nucifora, G., Larson, R.A., Rowley, J.D. (1993) Persistence of the 8; 21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood, 82, 712 715.
  • 19
    Ogata, K., Yokose, N., Ito, T., An, E., Tamura, H., Dan, K., Hamaguchi, H., Sakamaki, H., Onozawa, Y., Nomura, T. (1994) Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes. British Journal of Haematology, 86, 562 567.
  • 20
    Pessano, S., Palumbo, A., Ferrero, D., Pagliardi, G.L., Bottero, L., Lai, S.K., Meo, P., Carter, C., Hubbell, H., Lange, B., Rovera, G. (1984) Subpopulation heterogeneity in human acute myeloid leukemia determined by monoclonal antibodies. Blood, 64, 275 281.
  • 21
    Reading, C.L., Estey, E.H., Huh, Y.O., Claxton, D.F., Sanchez, G., Terstappen, L.W., O'brien, M.C., Baron, S., Deisseroth, A.B. (1993) Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood, 81, 3083 3090.
  • 22
    Sandberg, A.A. (1986) The chromosomes in human leukemia. Seminars in Hematology, 23, 201 217.
  • 23
    San Miguel, J.F., González, M., Canizo, M.C., Anta, J.P., Zola, H., Lopez, B.A. (1986) Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. British Journal of Haematology, 64, 547 560.
  • 24
    San Miguel, J.F., Martínez, A., Macedo, A., Vidriales, M.B., Lopez, B.C., González, M., Caballero, D., Garcia, M.M., Ramos, F., Fernandez, C.J., Calmuntia, M.J., Diaz, M.J., Orfao, A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 90, 2465 2470.
  • 25
    Stewart, C.C. & Stewart, S.J. (1994) Multiparameter analysis of leukocytes by flow cytometry. Methods in Cell Biology, Vol. 41 (ed. by Z. Darzynkiewicz, J.P. Robinson & H.A. Crissman), pp. 61 79. Academic Press, San Diego.
  • 26
    Tamura, H., Ogata, K., Dan, K., Nomura, T. (1997) Rationale and hematologic target points in response-oriented individualized induction chemotherapy for acute myeloid leukemia. International Journal of Hematology, 66, 325 334.DOI: 10.1016/s0925-5710(97)00050-9
  • 27
    Terstappen, L.W., Safford, M., Konemann, S., Loken, M.R., Zurlutter, K., Buchner, T., Hiddemann, W., Wormann, B. (1992) Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia, 6, 70 80.